CO5580844A2 - Queratinocitos utilizables como sustancia biologicamente activa en el tratamiento de heridas - Google Patents
Queratinocitos utilizables como sustancia biologicamente activa en el tratamiento de heridasInfo
- Publication number
- CO5580844A2 CO5580844A2 CO04035176A CO04035176A CO5580844A2 CO 5580844 A2 CO5580844 A2 CO 5580844A2 CO 04035176 A CO04035176 A CO 04035176A CO 04035176 A CO04035176 A CO 04035176A CO 5580844 A2 CO5580844 A2 CO 5580844A2
- Authority
- CO
- Colombia
- Prior art keywords
- keratinocytes
- duplicated
- cell culture
- vitro cell
- absence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
- C12N5/0629—Keratinocytes; Whole skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/40—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/60—Materials for use in artificial skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/395—Thyroid hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials Engineering (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Botany (AREA)
- Transplantation (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials For Medical Uses (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1.- Queratinocitos, caracterizados porque no están inmortalizados y que se duplican mediante procedimiento de cultivo celular in vitro al menos 150 veces.2.- Queratinocitos según la reivindicación 1, aislados de las porciones epidérmicas de un prepucio.3.- Queratinocitos según la reivindicación 1, caracterizados porque se trata de células del cultivo KC-BI-1 (DSM ACC 2514), o de queratinocitos derivados de ellas.4.- Queratinocitos según las reivindicaciones 1-3, no pudiéndose duplicar los citados queratinocitos a. en ausencia de suero fetal de ternera y/o b. en ausencia de células Feeder y/o c. en ausencia de factor de crecimiento epidérmico (EGF).5.- Queratinocitos según las reivindicaciones 1-4, no presentando los citados queratinocitos una baja o ninguna actividad de telomerasa, preferiblemente en comparación con queratinocitos inmortalizados, preferiblemente con la línea celular HaCaT.6.- Queratinocitos según las reivindicaciones 1-5, caracterizados porque los citados queratinocitos se pueden duplicar mediante procedimientos de cultivo celular in vitro al menos 200 veces.7.- Queratinocitos según las reivindicaciones 1-6, caracterizados porque los citados queratinocitos se pueden duplicar mediante procedimientos de cultivo celular in vitro al menos 250 veces.8.- Queratinocitos según las reivindicaciones 1-7, caracterizados porque los citados queratinocitos se duplican mediante procedimientos de cultivo celular in vitro al menos 300 veces.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10151296A DE10151296A1 (de) | 2001-10-17 | 2001-10-17 | Keratinozyten verwendbar als biologisch aktive Substanz bei der Behandlung von Wunden |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5580844A2 true CO5580844A2 (es) | 2005-11-30 |
Family
ID=7702826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO04035176A CO5580844A2 (es) | 2001-10-17 | 2004-04-16 | Queratinocitos utilizables como sustancia biologicamente activa en el tratamiento de heridas |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US7247478B2 (es) |
| EP (1) | EP1440148B1 (es) |
| JP (1) | JP4476625B2 (es) |
| KR (1) | KR101019916B1 (es) |
| CN (1) | CN100432220C (es) |
| AR (1) | AR036827A1 (es) |
| AT (1) | ATE474039T1 (es) |
| AU (1) | AU2002349352B2 (es) |
| BR (1) | BR0213282A (es) |
| CA (1) | CA2461141C (es) |
| CO (1) | CO5580844A2 (es) |
| DE (2) | DE10151296A1 (es) |
| DK (1) | DK1440148T3 (es) |
| EA (1) | EA009073B1 (es) |
| EC (1) | ECSP045065A (es) |
| ES (1) | ES2345767T3 (es) |
| HR (1) | HRP20040347B1 (es) |
| HU (1) | HU228887B1 (es) |
| IL (2) | IL161442A0 (es) |
| MX (1) | MXPA04003487A (es) |
| MY (1) | MY137828A (es) |
| NO (1) | NO334974B1 (es) |
| NZ (1) | NZ532899A (es) |
| PE (1) | PE20030627A1 (es) |
| PL (1) | PL367338A1 (es) |
| RS (1) | RS30104A (es) |
| UA (1) | UA81398C2 (es) |
| UY (1) | UY27486A1 (es) |
| WO (1) | WO2003033686A2 (es) |
| ZA (1) | ZA200402306B (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| WO2005012492A2 (en) * | 2003-08-01 | 2005-02-10 | Stratatech Corporation | Human skin equivalents expressing exogenous polypeptides |
| WO2006010161A2 (en) * | 2004-07-20 | 2006-01-26 | The Regents Of The University Of California | In vitro wound healing assay and device |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| UA97244C2 (en) | 2006-05-04 | 2012-01-25 | Берингер Ингельхайм Интернациональ Гмбх | Polymorphs of 1-((4-methyfquinazolin-2-yl)methyl)-3-methyl-7- (2-butyn-1-yl)-8-(3-(r)-aminopiperidin-l-yl)xanthine |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| EP2222893B1 (en) * | 2007-10-19 | 2017-01-04 | Biointraface, Inc. | Coating method |
| PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| CN102123717A (zh) | 2008-05-27 | 2011-07-13 | 普拉里斯坦有限公司 | 治疗炎性结肠疾病的方法 |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| CN102256976A (zh) | 2008-12-23 | 2011-11-23 | 贝林格尔.英格海姆国际有限公司 | 有机化合物的盐形式 |
| TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
| KR20190071840A (ko) | 2009-11-27 | 2019-06-24 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
| ES2935300T3 (es) | 2010-05-05 | 2023-03-03 | Boehringer Ingelheim Int | Combiterapia |
| US9096852B2 (en) * | 2010-06-09 | 2015-08-04 | Chanel Parfums Beaute | Inhibitors of micro-RNAs for use for preventing and/or attenuating skin ageing and/or for hydrating skin |
| CN106975074A (zh) | 2010-06-24 | 2017-07-25 | 勃林格殷格翰国际有限公司 | 糖尿病治疗 |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| US8883800B2 (en) | 2011-07-15 | 2014-11-11 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| EP2854824A1 (en) * | 2012-05-25 | 2015-04-08 | Boehringer Ingelheim International GmbH | Use of keratinocytes as a biologically active substance in the treatment of wounds, such as diabetic wounds, optionally in combination with a dpp-4 inhibitor |
| JP6615109B2 (ja) | 2014-02-28 | 2019-12-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｄｐｐ−４阻害薬の医学的使用 |
| CN105219697A (zh) * | 2014-07-04 | 2016-01-06 | 赫柏慧康生物科技无锡有限公司 | 一种人原代角质细胞分离制备的方法 |
| EP3132809A1 (en) | 2015-08-21 | 2017-02-22 | Bioskinco GmbH | Composition and products comprising senescent cells for use in tissue regeneration |
| US10668259B2 (en) | 2015-10-21 | 2020-06-02 | Materials Science Associates, LLC | Metal oxide and polymer controlled delivery systems, sunscreens, treatments, and topical coating applicators |
| EP3443112B1 (en) * | 2016-04-12 | 2020-08-05 | Unicyte EV AG | Isolation of extracellular vesicles (evs) from biological fluid samples |
| EP3468562A1 (en) | 2016-06-10 | 2019-04-17 | Boehringer Ingelheim International GmbH | Combinations of linagliptin and metformin |
| CN109055303A (zh) * | 2018-09-12 | 2018-12-21 | 山东麦德克斯生物科技有限公司 | 一种皮肤组织的构建方法 |
| RU2731065C1 (ru) * | 2019-12-24 | 2020-08-28 | Федеральное государственное бюджетное учреждение науки Институт биологии развития им. Н.К. Кольцова РАН (ИБР РАН) | Состав криоконсерванта для длительного хранения первичных кератиноцитов |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4016038A (en) * | 1968-04-01 | 1977-04-05 | Hayashibara Company | Process for preparing maltoses from starches |
| US4016036A (en) * | 1975-11-14 | 1977-04-05 | Massachusetts Institute Of Technology | Process for serially culturing keratinocytes |
| IT1207525B (it) | 1987-06-23 | 1989-05-25 | Ist Naz Ric Sul Cancro | Metodo per la preservazione difogli trapiantabili di epitelio coltivato in vitro vitale. |
| US5292655A (en) * | 1990-01-29 | 1994-03-08 | Wille Jr John J | Method for the formation of a histologically-complete skin substitute |
| IT1248934B (it) | 1990-06-01 | 1995-02-11 | Fidia Spa | Membrane forate biocompatibili,processi per la loro preparazione,loro impiego come supporto per la crescita in vitro di cellule epiteliali, pelli artificiali cosi' ottenute e loro impiego nei trapianti di pelle |
| US6585969B1 (en) * | 1991-11-20 | 2003-07-01 | N. V. Innogenetics S.A. | Non-viable keratinocyte cell composition or lysate for promoting wound healing |
| DK0615545T3 (da) | 1991-11-20 | 2000-10-30 | Innogenetics Nv | Lysater hidrørende fra keratinocytter til brug som sårhelingsmidler |
| US5518878A (en) | 1993-09-15 | 1996-05-21 | Organogenesis Inc. | Cryopreservation of cultured skin or cornea equivalents with agitation |
| US5891617A (en) * | 1993-09-15 | 1999-04-06 | Organogenesis Inc. | Cryopreservation of harvested skin and cultured skin or cornea equivalents by slow freezing |
| US5693332C1 (en) * | 1995-08-11 | 2001-01-09 | Univ California | Human keratinocytes supported on a hydrophilic membrane and methods of using same to effect wound closure |
| AUPP244498A0 (en) * | 1998-03-18 | 1998-04-09 | Medvet Science Pty. Ltd. | Keratinocyte stem cells |
| DE19917532A1 (de) | 1999-04-19 | 2000-10-26 | Christian Toloczyki | Trägergebundene kultivierte Stamm-bzw. Vorläuferzellen von Keratinozyten |
-
2001
- 2001-10-17 DE DE10151296A patent/DE10151296A1/de not_active Withdrawn
-
2002
- 2002-10-10 US US10/268,496 patent/US7247478B2/en not_active Expired - Fee Related
- 2002-10-14 CA CA2461141A patent/CA2461141C/en not_active Expired - Fee Related
- 2002-10-14 EP EP02781248A patent/EP1440148B1/de not_active Expired - Lifetime
- 2002-10-14 AT AT02781248T patent/ATE474039T1/de active
- 2002-10-14 AU AU2002349352A patent/AU2002349352B2/en not_active Ceased
- 2002-10-14 DK DK02781248.6T patent/DK1440148T3/da active
- 2002-10-14 HU HU0600341A patent/HU228887B1/hu not_active IP Right Cessation
- 2002-10-14 RS YU30104A patent/RS30104A/sr unknown
- 2002-10-14 KR KR1020047005677A patent/KR101019916B1/ko not_active IP Right Cessation
- 2002-10-14 DE DE50214540T patent/DE50214540D1/de not_active Expired - Lifetime
- 2002-10-14 JP JP2003536415A patent/JP4476625B2/ja not_active Expired - Fee Related
- 2002-10-14 IL IL16144202A patent/IL161442A0/xx unknown
- 2002-10-14 PL PL02367338A patent/PL367338A1/xx unknown
- 2002-10-14 EA EA200400482A patent/EA009073B1/ru not_active IP Right Cessation
- 2002-10-14 UY UY27486A patent/UY27486A1/es not_active Application Discontinuation
- 2002-10-14 BR BR0213282-6A patent/BR0213282A/pt active Pending
- 2002-10-14 UA UA20040503620A patent/UA81398C2/xx unknown
- 2002-10-14 WO PCT/EP2002/011459 patent/WO2003033686A2/de active Application Filing
- 2002-10-14 NZ NZ532899A patent/NZ532899A/en not_active IP Right Cessation
- 2002-10-14 CN CNB028207874A patent/CN100432220C/zh not_active Expired - Fee Related
- 2002-10-14 ES ES02781248T patent/ES2345767T3/es not_active Expired - Lifetime
- 2002-10-15 PE PE2002001015A patent/PE20030627A1/es not_active Application Discontinuation
- 2002-10-15 MY MYPI20023849A patent/MY137828A/en unknown
- 2002-10-16 AR ARP020103870A patent/AR036827A1/es not_active Suspension/Interruption
-
2004
- 2004-03-24 ZA ZA200402306A patent/ZA200402306B/en unknown
- 2004-04-14 MX MXPA04003487A patent/MXPA04003487A/es active IP Right Grant
- 2004-04-15 EC EC2004005065A patent/ECSP045065A/es unknown
- 2004-04-15 IL IL161442A patent/IL161442A/en not_active IP Right Cessation
- 2004-04-16 HR HRP20040347AA patent/HRP20040347B1/xx not_active IP Right Cessation
- 2004-04-16 CO CO04035176A patent/CO5580844A2/es not_active Application Discontinuation
- 2004-04-16 NO NO20041570A patent/NO334974B1/no not_active IP Right Cessation
-
2006
- 2006-11-03 US US11/556,367 patent/US7306943B2/en not_active Expired - Fee Related
-
2007
- 2007-10-31 US US11/930,880 patent/US7754481B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5580844A2 (es) | Queratinocitos utilizables como sustancia biologicamente activa en el tratamiento de heridas | |
| Olsson et al. | Repigmentation of vitiligo by transplantation of cultured autologous melanocytes. | |
| ES2147720T3 (es) | Factor de celulas madre. | |
| ATA165999A (de) | Medium zur protein- und serumfreien kultivierung von zellen | |
| ES2053719T3 (es) | Dimetilvermectinas no naturales y procedimiento para su preparacion. | |
| RU2007146777A (ru) | Получение линии эмбриональных стволовых клеток человека с использованием клеток млекопитающих | |
| HN1997000124A (es) | Lineas de celulas inmortalizadas para el desarrollo del virus. | |
| ES2181725T3 (es) | Inhibidores de hiv proteasa. | |
| BR9910251A (pt) | Estimulação hematopoiética | |
| AR003496A1 (es) | Procedimiento de tratamiento cosmetico no terapeutico de desordenes asociados con un exceso de sintesis y/o liberacion del cgrp y/o de sustancia p utilizacion de al menos un extracto de celulas de la menos un vegetal de la familia de las iridaceas y composicion cosmetica o farmaceutica que comprende dicho extracto | |
| ES2106086T3 (es) | Biomaterial a base de colageno y sus aplicaciones. | |
| DE60106056D1 (de) | Kollagenmembran mit makromolekularer anordnung | |
| ES2149779T3 (es) | Lisados derivados de queratinocitos para utilizacion como substancias cicatrizantes. | |
| Mol et al. | Grafting of venous leg ulcers: an intraindividual comparison between cultured skin equivalents and full-thickness skin punch grafts | |
| ATE342275T1 (de) | Vorübergehend-immortalisierte zellen zur verwendung in gentherapie | |
| PT1318198E (pt) | Processo para produzir um polipeptido recombinante que envolve a adicao de um inibidor de quimotripsina ao meio de cultura celular | |
| PT91971A (pt) | Metodo para a producao de camadas epidermicas de cultura | |
| CN105079783A (zh) | 药物组合物及其制备方法和用途 | |
| NZ506510A (en) | A permanent skin replacement comprising allogenic epithelial cells cultured in vitro and autologous epithelial cells | |
| MX9203409A (es) | Proteinas bcrfi como inhibidores de la gama interferona. | |
| Bowling et al. | Fabrication and reorganization of dermal equivalents suitable for skin grafting after major cutaneous injury | |
| ES2162331T3 (es) | Utilizacion del factor de crecimiento del tejido nervioso para conservacion, cultivo o tratamiento de la cornea. | |
| ATE521696T1 (de) | Verfahren zur herstellung von zelltransplantaten | |
| AU5380201A (en) | Method for expansion of epithelial stem cells | |
| ES2143990T3 (es) | Utilizacion de factores de crecimiento de hepatocitos para la fabricacion de un multiplicador de celulas cepa hematopoyeticas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |